When CFO Paul Lytle gave his 4-28-05 talk to the WallST-Reporter, one of his slides was titled “VTA Licensing Opportunities”:
[ The 2-2001 Supergen VEGF/rGel deal is #3 on the list. The 8-25-05 Medarex Anti-PSMA deal is #8 on the list. ]
“This is a slide that shows vascular targeting agents (VTAs). Now, a VTA is an antibody that is attached to a killing agent, such as VEGF attached to Ricin. Now, if you combine these two agents together to affect tumor vasculature, you fall under Peregrine VTA technologies. Each one of these lines represents some pre-clinical research that has some proof of efficacy and promising pre-clinical results that says these combinations work. Each one of these lines represents a future potential licensing opportunity and a future potential revenue stream.” VALIDATED VTAS (PRECLINICAL) - LICENSING OPPORTUNITIES 1. VEGF delivering Ricin 2. VEGF delivering Diptheria Toxin 3. VEGF delivering Gelonin <= Supergen 2-2001 4. Anti-VEGF:R-Complex delivering Ricin 5. Anti-MHC-Class2 delivering Ricin 6. Anti-MHC-Class2 delivering Tissue Factor 7. Anti-VCAM-1 delivering Tissue Factor 8. Anti-PSMA delivering Tissue Factor <=Medarex 8-2005 9. Anti-Endoglin delivering Ricin 10. Anti-Endoglin delivering Pseudomonas Exotoxin 11. Anti-Fibronectin ED-B delivering Tissue Factor 12. Anti-Fibronectin ED-B delivering IL-12 13. Anti-gp80(TES) delivering Neocarzinostatin 14. Anti-Lung Tumor Caveolar Protein delivering Ricin 15. Anti-AvB3 delivering Radionuclide 16. AvB3-Binding Peptide delivering Doxorubicin 17. Aminopeptidase-binding Peptide delivering Apoptosis-indicing Peptide ALSO: Anti-Phospholipid Antibodies (APTs) delivering anti-tumor and anti-viral drugs http://www.investorshub.com/boards/read_msg.asp?message_id=6189121
= = = = = = PPHM 10k yr-end 4-30-04: During February 2001, we completed a licensing deal with SuperGen, Inc. (“SuperGen”) to license a segment of our VTA technology, specifically related to Vascular Endothelial Growth Factor (“VEGF”). Under the terms of the licensing agreement, SuperGen purchased 150,000 shares of our common stock at $4.00 per share for total proceeds of $600,000. We also received an annual license fee of $200,000 in cash or SuperGen common stock until SuperGen files an Investigational New Drug Application in the United States utilizing the VEGF technology. As of April 30, 2004, SuperGen has not filed an Investigational New Drug Application in the United States utilizing the VEGF technology. The $200,000 annual license fee is included in license revenue in the accompanying consolidated financial statements for the years ended April 30, 2004, 2003 and 2002 in accordance with SAB No. 101 and SAB No. 104. In addition, we could receive additional milestone payments based on the development success, plus receive a royalty on net sales of all drugs commercialized by SuperGen utilizing the VEGF technology. We could also receive additional consideration for each clinical candidate that enters a Phase III clinical trial by SuperGen.
From SUPG’s 3-31-06 10K: From time to time we enter into collaborative relationships with third parties to co-develop and market products. For example, we entered into an agreement with Peregrine Pharmaceuticals in February 2001, pursuant to which we licensed a drug-targeting technology known as Vascular Targeting Agent, which is a proprietary platform designed to specifically target a tumor’s blood supply and subsequently destroy the tumor with various attached therapeutic agents. The licensed technology is specifically related to VEGF. Under the agreement, we made an up-front equity investment in Peregrine of $600,000 and will be obligated to make subsequent milestone payments that could ultimately total $8.25 million. In addition, we will pay royalties to Peregrine based on the net revenues of any drugs we commercialize using the VEGF technology. http://businessweek.brand.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingHTML1?SessionID=TP7ljNVju...
FYI, PPHM has Exclusive Rights to Thorpe’s VTA discoveries, incl. VEGF/rGel: 4-30-06 10K: In April 1997, in conjunction with the acquisition of Vascular Targeting Technologies, Inc. (formerly known as Peregrine Pharmaceuticals, Inc.), we gained access to certain exclusive licenses for Vascular Targeting Agents (“VTAs”) technologies from various institutions. In conjunction with various licensing agreements covering our VTA technology, we are required to pay combined annual fees of $50,000 plus milestone payments based on the development success of the technologies and a royalty on net sales. Our aggregate future milestone payments under these exclusive licenses are $1,688,000 assuming the achievement of all development milestones under the agreements through commercialization of the product, which are due at various stages of clinical development in accordance with the applicable license. We do not anticipate making any milestone payments for at least the next year under these agreements. http://www.sec.gov/Archives/edgar/data/704562/000101968706001670/peregrine_10k-043006.htm
News 
Market Data 
Discover 
AI
